Martina Meijboom

Learn More
The use of zoledronic acid (ZOL) has recently been shown to significantly reduce the risk of new skeletal-related events (SREs) in renal cell carcinoma (RCC) patients with bone metastases. The… (More)
  • ‹
  • 1
  • ›